XENE
Xenon Pharmaceuticals·NASDAQ
--
--(--)
--
--(--)
4.95 / 10
Netural
Analyst sentiment is overwhelmingly bullish (100% Buy) from JP Morgan, yet the fund-flow picture is nuanced: overall inflow ratio of 0.475 indicates mild buying pressure, but all size brackets (Small to Extra-large) show negative trends. The 7.69 fund-flow score is good, but the conflicting signals between analyst ratings and money flows call for caution.
Fund Flow Rating
Analyst RatingBuy
Wall Street Opinions
Buy
Strong Buy
0%
Buy
100%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-09
InstitutionJP Morgan
Times predicted2
Historical Win Rate50.0%
What is the analyst consensus for XENE?
- XENE holds a Bearish analyst rating, with 100% of experts assigning a Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 4.95/10 (Netural).
